Topic: nonalcoholic steatohepatitis (NASH)
The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.
In the draft, the FDA sets out the endpoints and patient populations it wants companies to look at in phases 2 and 3.
Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.
Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.
Gilead unveiled phase 2 data showing its FXR agonist improved liver biochemistry and cholestasis in patients with primary sclerosing cholangitis.
Seal Rock Therapeutics is officially launching with plans to bring its lead asset, an ASK1 inhibitor for NASH, into human trials in 2020.
Terns Pharmaceuticals has bagged $80 million to bankroll a pipeline of drugs for nonalcoholic steatohepatitis acquired from Eli Lilly.
Pfizer is joining forces with Novartis to treat NASH and try to get a slice of a potentially multibillion-dollar future market.
89Bio has raised $60 million to advance a stable of small molecules and biologics acquired from Teva.
Glympse Bio, a startup that builds bioengineered in vivo sensors for disease, has emerged from stealth with a $22 million series A round.